MedTrace Logo

An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

NCT00696995 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 509

Last updated 2017-01-09

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696995 on ClinicalTrials.gov